



# Hypoxia drives glucose transporter 3 expression through hypoxia-inducible transcription factor (HIF)–mediated induction of the long noncoding RNA NICI

Received for publication, June 18, 2019, and in revised form, October 18, 2019. Published, Papers in Press, November 5, 2019, DOI 10.1074/jbc.RA119.009827

Victoria Lauer<sup>‡</sup>, Steffen Grampp<sup>‡</sup>, James Platt<sup>§</sup>, Veronique Lafleur<sup>§</sup>,  Olivia Lombardi<sup>§</sup>, Hani Choudhry<sup>¶</sup>, Franziska Kranz<sup>¶||</sup>, Arndt Hartmann<sup>\*\*</sup>, Bernd Wullich<sup>††</sup>, Atsushi Yamamoto<sup>§</sup>, Mathew L. Coleman<sup>§§</sup>, Peter J. Ratcliffe<sup>§</sup>, David R. Mole<sup>§</sup>, and Johannes Schödel<sup>†‡1</sup>

From the <sup>‡</sup>Department of Nephrology and Hypertension, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Ulmenweg 18, 91054 Erlangen, Germany, <sup>§</sup>NDM Research Building, University of Oxford, Old Road Campus, Headington, Oxford OX3 7FZ, United Kingdom, <sup>¶</sup>Department of Biochemistry, Faculty of Science, Center of Innovation in Personalized Medicine, King Fahd Center for Medical Research, King Abdulaziz University, Jeddah, Saudi Arabia, <sup>||</sup>Department of Computer Science 9, Friedrich-Alexander-Universität Erlangen-Nürnberg, Cauerstraße 11, 91058 Erlangen, Germany, <sup>\*\*</sup>Institute of Pathology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Krankenhausstraße 8–10, 91054 Erlangen, Germany, <sup>††</sup>Department of Urology and Pediatric Urology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Krankenhausstraße 12, 91054 Erlangen, Germany, <sup>§§</sup>Institute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom

Edited by John M. Denu

Hypoxia-inducible transcription factors (HIFs) directly dictate the expression of multiple RNA species including novel and as yet uncharacterized long noncoding transcripts with unknown function. We used pan-genomic HIF-binding and transcriptomic data to identify a novel long noncoding RNA Noncoding Intergenic Co-Induced transcript (NICI) on chromosome 12p13.31 which is regulated by hypoxia via HIF-1 promoter-binding in multiple cell types. CRISPR/Cas9-mediated deletion of the hypoxia-response element revealed co-regulation of NICI and the neighboring protein-coding gene, solute carrier family 2 member 3 (*SLC2A3*) which encodes the high-affinity glucose transporter 3 (GLUT3). Knockdown or knockout of NICI attenuated hypoxic induction of *SLC2A3*, indicating a direct regulatory role of NICI in *SLC2A3* expression, which was further evidenced by CRISPR/Cas9-VPR-mediated activation of NICI expression. We also demonstrate that regulation of *SLC2A3* is mediated through transcriptional activation rather than posttranscriptional mechanisms because knockout of NICI

leads to reduced recruitment of RNA polymerase 2 to the *SLC2A3* promoter. Consistent with this we observe NICI-dependent regulation of glucose consumption and cell proliferation. Furthermore, NICI expression is regulated by the von Hippel-Lindau (VHL) tumor suppressor and is highly expressed in clear cell renal cell carcinoma (ccRCC), where *SLC2A3* expression is associated with patient prognosis, implying an important role for the HIF/NICI/*SLC2A3* axis in this malignancy.

Hypoxia is a critical feature of many physiological and pathophysiological conditions (1). Hypoxia-inducible transcription factors (HIFs)<sup>2</sup> are a major component of the transcriptional response to oxygen deprivation (2). Upon hypoxic exposure HIF- $\alpha$  subunits (HIF-1 $\alpha$  and HIF-2 $\alpha$ ) are stabilized in the cell, following which they dimerize with HIF-1 $\beta$  and translocate into the nucleus to stimulate transcription of genes relevant for multiple regulatory pathways involved in cellular and organismal adaptation to the hypoxic insult (e.g. metabolism, cell cycle, red blood cell production, and angiogenesis) (3, 4). The HIF pathway can be activated in all tissues and is currently exploited pharmacologically in patients with chronic kidney disease to increase erythropoietin production (5). Beside their physiological functions, HIFs are also important modulators of several human diseases and associated pathological processes, including tumorigenesis (6). The direct relevance of HIFs for cancer progression has been most clearly demonstrated in clear cell renal cell carcinoma (ccRCC), which in most cases is caused by loss of the von Hippel-Lindau (VHL) tumor suppressor (7–10).

This work was supported by Interdisciplinary Center for Clinical Research Erlangen Grant Project J31 (to J. S.); Cancer Research UK Grant A416016 (to D. R. M.); the National Institutes of Health Research Grant NIHR-RP-2016-06-004 (to D. R. M.); the Deanship of Scientific Research, King Abdulaziz University, Ministry of High Education for Saudi Arabia (to H. C., D. R. M. and P. J. R.); the Ludwig Institute for Cancer Research (to P. J. R.); the Wellcome Trust Grants 088182/Z/09/Z, 078333/Z/05/Z, and WT091857MA (to P. J. R.); and the Francis Crick Institute (to P. J. R.), which receives its core funding from Cancer Research UK Grant FC001501; the UK Medical Research Council Grant FC001501; and the Wellcome Trust Grant number FC001501. Funding was received from the Deutsche Forschungsgemeinschaft Grant SCHO 1598/1-1 and Grant 387509280–SFB 1350 C5 (to J. S.) and the Else Kroener-Fresenius Stiftung Grant 2014\_EKES.11 (to J. S.). The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

✂ Author's Choice—Final version open access under the terms of the Creative Commons CC-BY license.

This article contains Figs. S1–S9 and Tables S1–S2.

<sup>1</sup> To whom correspondence should be addressed. Tel.: 09131-85-39560; Fax: 09131-85-39561; E-mail: johannes.schoedel@uk-erlangen.de.

This is an Open Access article under the CC BY license.

<sup>2</sup> The abbreviations used are: HIF, hypoxia-inducible factor; ASO, antisense oligonucleotide; CAT, cancer associated transcript; ccRCC, clear cell renal cell carcinoma; DMOG, dimethylxylglycine; gRNA, guide RNA; HRE, hypoxia response element; lncRNA, long noncoding RNA; NICI, noncoding intergenic co-induced; PTC, primary tubular cell; TCGA, The Cancer Genome Atlas; VHL, von Hippel-Lindau.

## Long noncoding RNA NIC1 regulates GLUT3 expression

VHL-dependent ubiquitination is necessary for proteasomal degradation of the HIF- $\alpha$  subunits in normoxic conditions. Therefore, dysfunctional VHL leads to stabilization of HIFs irrespective of oxygen availability, thereby contributing to the development and progression of renal cancer (11).

HIFs can activate the expression of a multitude of metabolic enzymes and transporters to optimize energy production in hypoxia (1, 12). Together, this HIF-mediated transcriptional reprogramming of metabolism supports a shift toward anaerobic energy production. For example, increased glycolysis during hypoxia is supported by HIF-mediated induction of glucose transporters, including solute carrier family 2 member 1 (*SLC2A1*, coding for glucose transporter 1 (GLUT1)) and *SLC2A3* (coding for GLUT3) (13, 14). Although the overall increase in expression of *SLC2A1* and *SLC2A3* by hypoxia and HIF is well-documented, detailed mechanisms of transcriptional regulation of these transporter genes by HIF are less well-defined (13–17).

The repertoire of protein-coding genes activated by HIF has been studied extensively by transcriptome analyses in a variety of cellular settings and, beside a small number of ubiquitous HIF targets (including *SLC2A3*), displays marked cell type specificity (15). Recent work suggests that HIFs also dictate the expression of several classes of nonprotein coding genes, such as micro-RNA and long noncoding RNAs (18). For example, the micro-RNA mir210 has been identified as a direct target of HIF, and its expression is associated with poor or favorable prognosis, respectively, depending on the type of cancer examined (19, 20). The long noncoding RNAs NEAT1 and MALAT1 are also subject to hypoxic regulation and have important roles in tumor biology (21). These findings are in line with recent pan-genomic analyses of transcriptional dysregulation in a variety of diseases which have highlighted the importance of long noncoding transcripts in disease progression (22). However, the potential breadth of long noncoding RNA regulation in hypoxia, and the role of such targets in the hypoxic response, is not yet fully understood.

In recent work, we characterized global HIF-DNA interactions and transcriptional changes mediated via hypoxia in MCF-7 breast cancer cells (4, 18). We observed transcriptional activation of all classes of RNAs by HIF and identified multiple novel and previously nonannotated RNAs with low protein-coding potential. These RNAs were barely detectable in cells exposed to ambient atmospheric oxygen conditions but were highly up-regulated in hypoxia through HIF. Here we investigate the function and regulation of a novel hypoxia-specific long noncoding RNA (NIC1) that is directly targeted by HIF. Importantly, we demonstrate that NIC1 is co-regulated with a neighboring gene, *SLC2A3*. Our analysis revealed a complex and noncanonical regulation of *SLC2A3* expression which is critically dependent on the presence of NIC1.

### Results

#### HIF controls expression of a promoter-associated long noncoding RNA on chromosome 12p13.31


To gain insights into the regulation of novel transcripts, we intersected existing HIF DNA-binding data in MCF-7 breast

cancer cells (400 HIF-1 and 425 HIF-2 binding sites) with 37 loci expressing novel RNAs regulated by hypoxia (4, 18). We showed earlier that all of these transcripts have low protein coding potential (18). Most of the RNAs ( $n = 35$ ) were induced by hypoxia and were at the limit of detection under normoxic conditions. Of the 37 regions expressing novel nonannotated RNAs, 10 were adjacent to HIF-binding events (HIF-1 and HIF-2) within  $\pm 10$  kb of the putative transcriptional start site (Table S1). These results suggest that HIF binding directly activates transcription of a substantial part of the novel, hypoxia-regulated, nonannotated transcripts in MCF-7 cells.

One novel transcript with HIF ChIP-Seq signals close to the coding region is located on chromosome 12p13.31 (Fig. 1, *a* and *b*) (18). We used RNAPol2 ChIP-Seq in MCF-7 cells cultured under normoxic or hypoxic conditions to assay for transcriptional activity at this locus. The presence of RNAPol2 increased in hypoxia, suggesting that elevated levels of the transcript result from *de novo* transcription (Fig. 1*b*). To test for HIF-dependent transcription we interrogated available RNA-Seq data sets from MCF-7 cells cultured in hypoxia with suppressed HIF levels (Fig. 1*c*) (18). Although suppression of HIF-2 $\alpha$  had some effect on the hypoxic induction of the transcript, suppression of HIF-1 $\alpha$  resulted in a more pronounced reduction of hypoxic expression, indicating that the transcript is predominantly regulated by HIF-1. We also screened existing databases of long noncoding RNAs derived from cancer transcriptomes and discovered that three cancer-associated transcripts (CAT) overlap this region (CAT1466.1, CAT1466.2, and CAT1466.3) (22). From our RNA-Seq data we infer that CAT1466.1 is identical to the transcript which is regulated by HIF (Fig. 1*d*). We further analyzed epigenetic features at the HIF-binding site and detected high levels of the promoter-associated histone mark H3K4me3 and low levels of the enhancer histone mark H3K4me1 in MCF-7 cells (Fig. S1). Moreover, the levels of H3K4me3 and the activity mark H3K27ac increased upon hypoxic exposure indicating that CAT1466.1 is induced from a genuine promoter, rather than expressed as an enhancer-RNA (eRNA) (Fig. S1). This finding is in line with data from genome-wide analyses defining promotor- and enhancer-linked genomic regions which revealed strong evidence for promotor-associated features at this site (23, 24).

#### The long noncoding RNA NIC1 is co-expressed with *SLC2A3*

To date the function of long noncoding RNAs remains poorly understood. However, a number of long noncoding RNAs have a role in the cis-regulation of neighboring coding genes (25). We therefore determined the extent of regulation of CAT1466.1 compared with *SLC2A3*, which is the closest annotated gene  $\sim 35$  kb downstream of CAT1466.1. We exposed a broad selection of different human cell lines to the HIF stabilizer dimethylxalylglycine (DMOG) or 1% hypoxia for 16 h and measured expression of *SLC2A3* and CAT1466.1 by quantitative PCR (qPCR) (Fig. 2*a* and Fig. S2). We detected significant and in general comparable levels of induction of *SLC2A3* and CAT1466.1 by DMOG or hypoxia, respectively. Increased expression for both genes was observed in most cells examined except for 786-O VHL re-expressing cells, which lack functional HIF-1 $\alpha$  (9, 26). Given the striking co-regulation, we sug-



**Figure 1. HIF-1 induces expression of a long noncoding RNA on chr 12p13.31.** *a* and *b*, RNA-Seq tracks (*a*) and ChIP-Seq tracks (*b*) indicate induction of a transcript, HIF binding (HIF-1 $\alpha$ , HIF-2 $\alpha$ , and HIF-1 $\beta$ ) and increased RNA-polymerase 2 activity (RNAPol2) in hypoxia at an intergenic site on chr 12p13.31 in MCF-7 breast cancer cells. *c*, RNA-Seq from HIF-siRNA-treated MCF-7 cells cultured in hypoxia reveals a predominant HIF-1 dependence of the long noncoding RNA at this site. *d*, the region overlaps with CAT derived from mitranscriptome.org<sup>3</sup> (50) from which CAT1466.1 resembles the novel transcript.

gested the name Noncoding Intergenic Co-Induced transcript (NICI) for the long noncoding RNA CAT1466.1. Consistent with an important role of HIF-1 $\alpha$ , HIF knockdown experiments confirmed HIF-1 $\alpha$  as the main inducer of both NICI and SLC2A3 in a subset of tested cell lines (Fig. S3, *a–c*). To verify the association of NICI and SLC2A3 expression with HIF binding across cell types, we inspected available HIF ChIP-Seq and RNA-Seq data from additional cell lines (primary renal tubular cells (PTC), RCC4, HKC-8, T47D) for signals in this region. These analyses confirmed a single HIF-binding site in the broader genomic region of SLC2A3 which corresponded to the NICI promoter and regulation of both genes by hypoxia (Fig. 2*b* and Fig. S4). We also examined for regulation of additional neighboring mRNA transcripts (within 1Mb of the novel locus) by hypoxia in available RNA-Seq data sets, but did not detect hypoxic regulation of any other gene in this region (data not shown). We proceeded to analyze this co-regulation in more detail: Expression levels of NICI and SLC2A3 were highly induced in primary renal tubular cell cultures ( $n = 16$ ) treated with DMOG (Fig. 2*c*). Furthermore, NICI RNA levels correlated well with those of SLC2A3, consistent with a shared mode of transcriptional activation (Fig. 2*d*). In this respect we considered the existence of a common RNA from which both transcripts arise, *e.g.* through alternative promoter usage. However, we could not detect the presence of RNAPol2 or any transcript in the intergenic region between SLC2A3 and NICI (Fig. 2*b* and Fig. S4) (data not shown). We were also unable to detect spliced RNA products which cover both transcripts by PCR (data not


shown). In addition, in time-course experiments we measured a delayed hypoxic induction of SLC2A3 mRNA compared with NICI RNA (Fig. 2*e*). This indicates that NICI and SLC2A3 expression is regulated from autonomous promoters. Our data suggest that hypoxic regulation of NICI and SLC2A3 is mediated via HIF binding to a single regulatory element which is conserved across the cell lines tested.

### Regulation of NICI in renal cancer


Following up on the evidence for co-regulation of NICI and SLC2A3 by HIF, we also examined regulation of these genes in ccRCC, in which HIF target genes are commonly up-regulated. We measured expression levels of both genes in VHL-deficient (high levels of HIF) and VHL-re-expressing (low levels of HIF) renal cancer cell lines (RCC4 and RCC10) exposed to control or DMOG conditions (Fig. 3*a*). Here, we determined a significant reduction of both SLC2A3 and NICI RNA levels in cells re-expressing VHL compared with VHL-deficient cells. The expression of both genes was restored in VHL re-expressing cells following HIF stabilization by DMOG, thus confirming the regulatory role of the VHL/HIF-axis in NICI and SLC2A3 expression.

Next, we proceeded to determine the RNA levels of NICI and SLC2A3 in 161 renal tumor and corresponding normal kidney samples collected from RCC patients from the Erlangen RCC cohort (126 ccRCC and 35 non-ccRCC patients including papillary and chromophobe RCCs) (28). NICI and SLC2A3 RNA were significantly up-regulated in tumor samples from ccRCC patients, but not in nonclear cell tumors, supporting the strong association with the HIF pathway (Fig. 3*b*). These results were also observed in data from the TCGA database: Expression levels of SLC2A3 and NICI (CAT1466.1) were highest in ccRCC

<sup>3</sup> Please note that the JBC is not responsible for the long-term archiving and maintenance of this site or any other third party hosted site.




## Long noncoding RNA NICI regulates GLUT3 expression



**Figure 3. Expression of NICI and SLC2A3 in renal cancer.** *a*, NICI and SLC2A3 are regulated via VHL and HIF. Expression qPCR analysis of renal cancer cell lines RCC4 VHL ± and RCC10 VHL ± were treated with 1 mM DMOG for 16 h or left untreated. Values are mean ± S.D. from three independent experiments. *b*, box-and-whisker plot of RNA expression levels of NICI and SLC2A3 in samples from ccRCC ( $n = 126$ ) and non-ccRCC ( $n = 35$ ) from the Erlangen RCC cohort compared with corresponding normal renal tissue. Values were measured by qPCR and normalized to the expression levels of actin B (*ACTB*). The horizontal lines represent the average value, and the whiskers extend to the 10th and 90th percentile, respectively. Statistical analyses were performed using the two-sample *t* test (\*,  $p < 0.05$ ; \*\*,  $p < 0.01$ ; \*\*\*,  $p < 0.001$ ; \*\*\*\*,  $p < 0.0001$ ). *c*, Kaplan-Meier survival curve of renal cancer patients from the TCGA kidney renal clear cell carcinoma cohort stratified for high (red) or low (blue) SLC2A3 expression. Data were derived from oncolnc.org<sup>3</sup> (49).

**Figure 2. SLC2A3 and NICI are co-regulated by HIF-1.** *a*, relative NICI and SLC2A3 RNA expression levels (compared with untreated control) in a selection of human cell lines exposed to 1 mM DMOG for 16 h as measured by qPCR (mean ± S.D. from three independent experiments per cell line). Statistical analyses were performed using the one-sample *t* test (\*,  $p < 0.05$ ; \*\*,  $p < 0.01$ ; \*\*\*,  $p < 0.001$ ; \*\*\*\*,  $p < 0.0001$ ). *b*, ChIP-Seq analysis in PTCs confirms the single HIF-binding site at the CAT1466.1/NICI locus ~35 kb upstream of *SLC2A3*. Expression of NICI and SLC2A3 is induced upon HIF-stabilization with 1 mM DMOG in RNA-Seq experiments. *c*, mRNA expression of NICI and SLC2A3 in a collection of 16 PTC cultures left untreated or treated with 1 mM DMOG for 16 h. *d*, expression levels of NICI correlate well with those of SLC2A3 in DMOG-treated PTC. *e*, time course of relative expression levels of NICI and SLC2A3 RNA in PTC exposed to 1 mM DMOG for the indicated time. Data are normalized to time point 0 h and bars represent mean ± S.D. measured in cells from  $n = 3$  individuals.



**Figure 4. HIF-binding to the *NICI* locus regulates *SLC2A3* expression.** *a*, the HRE (*HRE mut*) targeted by a specific guide RNA and CRISPR/Cas9-mediated genome editing is highlighted in orange in the *NICI* promoter. *b*, HIF-binding to the *NICI* HRE and the control locus *EGLN3* in *NICI* HRE-mutated clones ( $n = 2$ ) and a control clone of cells is shown by ChIP-qPCR (values are from three independent experiments). *c*, relative RNA expression levels of untreated or DMOG (1 mM for 16 h) stimulated HeLa WT cells (*wt*) or clones with (*HRE mut*#1 and *HRE mut*#2) or without (*HRE mut control*) mutations in the HRE ( $n = 6$  independent experiments). Data represent mean  $\pm$  S.E. Statistical analyses were performed using the Student's *t* test (\*,  $p < 0.05$ ; \*\*,  $p < 0.01$ ; \*\*\*,  $p < 0.001$ ; \*\*\*\*,  $p < 0.0001$ ).

samples when compared with levels from other tumor entities available in the database (Fig. S5). Interestingly, in the TCGA kidney renal clear cell carcinoma cohort high *SLC2A3* mRNA expression was associated with an adverse prognosis (Fig. 3c). Taken together, our data from renal tumor cells and patients as well as data from the TCGA database underline the link between *NICI*/*SLC2A3* regulation and the VHL/HIF pathway. The results also point to a relevant role of this regulation for the outcome of renal cancer patients.


#### A single HIF-binding site regulates *NICI* and *SLC2A3* expression

To gain more detailed insights into how binding of HIF to a single site on chromosome 12 activates the transcription of two genes we performed CRISPR/Cas9-mediated manipulation of the HIF-binding sequence. We conducted this in HeLa cells which showed consistent induction of both genes by HIF-1 (compare Fig. 2a and Fig. S3c). The core sequence of the HIF-binding site in the *NICI* promoter (hg19 chr12:8,123,206–8,123,563 as defined by HIF-ChIP-Seq in MCF-7) contains three hypoxia response elements (HRE) (Fig. S6a) (4). We targeted the two HREs in the center of this region in CRISPR/Cas9 experiments (Fig. 4a and Fig. S6, a and b). In HIF-ChIP assays in HeLa cells, mutation of these core HREs significantly reduced HIF binding compared with control clones of cells or WT HeLa

cells (Fig. 4b) (data not shown). Importantly, these effects were specific because HIF-binding to the *EGLN3* intronic enhancer at chromosome 14 was not affected by mutations at the *NICI* HRE indicating a preserved HIF response at another locus in the mutated cells (Fig. 4b). To examine transcriptional consequences of reduced HIF binding to the *NICI* HRE, we determined expression levels of *NICI* and *SLC2A3* in HRE-defective and -nondefective cells upon DMOG exposure. Consistent with their co-regulation, we observed a reduced induction of both transcripts in HRE-mutated cells (Fig. 4c). Thus, we have identified a specific HIF-binding DNA element that is capable of regulating expression of two genes, the more proximal long noncoding RNA *NICI* and the more distal glucose transporter *SLC2A3*.

#### HIF regulates *SLC2A3* expression via induction of *NICI*

HIF is able to regulate genes with transcriptional start sites that lie at distances varying from a few base pairs to several hundred kilobases away from the binding site and that are brought together through chromatin looping (4, 29). Therefore, the single HIF-binding site on chr12p.13.31 could transactivate both *NICI* and *SLC2A3* independently. Alternatively, the regulation of either *NICI* or *SLC2A3* could be dependent upon regulation of the other. To test this, we first looked for physical




**Figure 5. Activation of NICI expression is necessary for SLC2A3 regulation.** *a*, Capture-C assay reveals chromatin interaction between the *SLC2A3* promoter (anchor site, highlighted in light green) and an intergenic site ~24 kb upstream of the promoter (highlighted in gray) in 786-O, RCC4, and MCF-7 cells. No interactions were detected with the *NICI* promoter (highlighted in light blue). *b*, knockdown of NICI in HeLa cells using two different ASO targeting NICI (NICI 1 and NICI 2), a nontargeting scrambled control (*Scr.*) and an ASO targeting the long noncoding RNA NEAT1 ( $n = 6$  independent experiments). Expression qPCR from DMOG-treated (1 mM for 16 h) and untreated cells was performed for NICI and *SLC2A3* RNA. Values were normalized to Hypoxanthine-guanine phosphoribosyltransferase (HPRT) and untreated scrambled control samples. *c*, epigenetic modulation of the *NICI* promoter by the activator CRISPR/Cas9-VPR leads to increased NICI and *SLC2A3* expression ( $n = 6$  independent experiments). Four different guide RNAs against the *NICI* promoter, pSPsgRNA empty vector or an independent guide RNA targeting the IL1R promoter were used. Values were normalized to results from pSPsgRNA control samples. Statistical analyses were performed using the one-sample *t* test (\*,  $p < 0.05$ ; \*\*,  $p < 0.01$ ; \*\*\*,  $p < 0.001$ ; \*\*\*\*,  $p < 0.0001$ ).

interaction of the *SLC2A3* promoter with the HIF-binding site at the putative *NICI* promoter. We performed chromatin capture assays in three different cell lines (786-O, RCC4, and MCF-7). We used sequences in the *SLC2A3* promoter as anchor sites and examined possible interactions with any distant chromatin region using the Capture-C method (Fig. 5a) (29, 30). Although we determined interactions with a putative enhancer site ~24 kb upstream of the *SLC2A3* promoter, no interaction was observed with the HIF-binding site, which regulates *NICI* and *SLC2A3* expression. This finding suggests that induction of *SLC2A3* expression by HIF is not initiated through direct interaction between the *SLC2A3* promoter and the HIF-binding site at the *NICI* promoter (*i.e.* acting as a distant enhancer of

*SLC2A3*) but may instead be mediated via the induction of *NICI* and subsequent regulation of *SLC2A3* transcription.

Long noncoding RNAs can be involved in transcriptional regulation of neighboring genes by various mechanisms, including recruitment of transcriptional modulators (*e.g.* activators or repressors) or direct interaction with the target transcript (31). Despite the lack of direct interaction between the HIF-binding site and the *SLC2A3* promoter the strong association between HIF-binding and expression of both genes as well as the delayed induction of *SLC2A3* compared with *NICI* (Fig. 2e) suggests a functional role for *NICI* in regulating *SLC2A3* expression. To validate this hypothesis, we first suppressed the expression of *NICI* using two different antisense oligonucleo-




**Figure 6. NIC1 mediates hypoxic SLC2A3 induction.** *a*, the site within the NIC1 transcript targeted by the guide RNA for CRISPR/Cas9-mediated mutation is highlighted in green (NIC1 mut). *b*, HIF ChIP-qPCR for the NIC1 HRE and the control HRE in the EGLN3 intronic region. DNA fragments were captured by ChIP using HIF-1β antibodies or serum control in clones with mutations in the NIC1 transcript (NIC1 mut) *n* = 4 independent clones) or control clones (control; *n* = 4 independent clones). Cells were exposed to 1 mM DMOG for 16 h. *c*, expression qPCR for NIC1 and SLC2A3 in untreated or DMOG-treated clones with (NIC1 mut; *n* = 9 independent clones) or without mutations in the NIC1 transcript (control; *n* = 5 independent clones). Results are from three independent experiments for each clone of cells. *d*, RNA polymerase 2 (RNAPol2) DNA interactions were determined by ChIP qPCR at the NIC1 HRE and the SLC2A3 transcriptional start site (TSS) in NIC1 transcript-mutated clones (*n* = 4) compared with control clones (*n* = 4). Cells were exposed to 1 mM DMOG for 16 h.

tides (ASOs) in HeLa cells. We achieved 80 and 50% knock-down efficiency of NIC1 in hypoxia with NIC1 ASO1 and ASO2, respectively (Fig. 5b). In line with our hypothesis, depletion of NIC1 resulted in a comparable reduction of SLC2A3 mRNA expression. Similar results for the effect of NIC1 knockdown on SLC2A3 mRNA and protein levels were obtained in PTC (Fig. S7). This suggests that NIC1 expression is necessary for hypoxic induction of SLC2A3. To show that NIC1 expression is sufficient to induce SLC2A3, we used a CRISPR/Cas9 approach to induce transcription of NIC1 in a HIF-independent manner. We co-transfected the CRISPR/Cas9-VPR transcriptional activator with four different guide RNAs (gRNAs) targeting the core HIF-binding sequence including the sequence spanning the HRE within the NIC1 promoter into HeLa cells. Increased

expression of NIC1 was observed with three of the four guide RNAs when compared with control guides (Fig. 5c). Importantly, these three gRNAs also increased levels of SLC2A3 mRNA, although only two reached statistical significance. Because these experiments were conducted under normoxia, we conclude that activation of NIC1 transcription is sufficient to induce SLC2A3 expression.

#### Knockout of NIC1 affects RNAPol2 recruitment to the SLC2A3 promoter and cell proliferation

To further dissect the mechanism of hypoxic SLC2A3 regulation and the role of NIC1, we performed CRISPR/Cas9-mediated deletion of the NIC1 transcript in HeLa cells (Fig. 6a). To minimize effects on transcription factor binding at the NIC1



**Figure 7. NICI regulates glucose consumption and proliferation.** *a* and *b*, glucose consumption (*a*) and lactate (*b*) in culture media from hypoxic cells. Cells ( $n = 2$  for HRE mut,  $n = 3$  for NICI mut,  $n = 4$  for mut control) were cultured in 1 mM DMOG for 24 h before glucose consumption and lactate were measured in the medium. *c*, MTS proliferation assay with cells from *a* performed in triplicates per time point under hypoxic conditions (1% O<sub>2</sub>). Statistical analyses were performed using the one- or two-sample *t* test (\*,  $p < 0.05$ ; \*\*,  $p < 0.01$ ; \*\*\*,  $p < 0.001$ ; \*\*\*\*,  $p < 0.0001$ ) comparing values from NICI/HRE mutated cells to the respective values from control clones (mut control).

promoter, we targeted a region ~330 bp downstream of the functional HRE and outside any potential transcription factor-binding sites as detected in Encyclopedia of DNA Elements analyses (Fig. S6c) (data not shown). Nine clones harboring mutations in the *NICI* coding region that did not affect the core HRE or other putative regulatory regions were generated (Fig. S6c). Importantly, mutations in the gene body of *NICI* did not alter HIF binding to the *NICI* HRE or the *EGLN3* HRE (Fig. 6b). However, mutation of *NICI* led to significantly reduced induction of both *NICI* and *SLC2A3* RNA by DMOG when compared with control clones (Fig. 6c). To examine whether the regulation of *SLC2A3* by *NICI* is mediated directly through transcriptional activation, we performed RNApol2 ChIP under DMOG treatment (Fig. 6d). As expected from the HIF-ChIP experiments (Fig. 6b), RNApol2 was recruited to the HIF-binding site in the *NICI* promoter following DMOG treatment, which was unaffected by mutations in the *NICI* gene. Importantly however, recruitment of RNApol2 to the *SLC2A3* promoter by DMOG was significantly reduced in *NICI*-mutated clones, indicating a direct role of *NICI* in transcriptional activation of *SLC2A3* expression (Fig. 6d). Finally, to test for functional consequences of HRE and *NICI* mutations in metabolic and growth responses we measured glucose consumption, lactate production, and proliferation in HeLa cells under hypoxia (Fig. 7, a–c). Interestingly, mutations in either the *NICI* HRE or the *NICI* gene body caused a remarkable reduction in glucose consumption, lactate production, and proliferation in HeLa cells under hypoxic conditions. Importantly, hypoxic induction of *SLC2A1* (GLUT1), the other glucose transporter targeted by HIF, was not compromised by mutations in the *NICI* gene (Fig. S8). This suggests that binding of HIF at the *NICI* locus and activation of *NICI* is important for cell growth under hypoxia and that this

effects is mediated by regulation of the *SLC2A3* isoform of glucose transporters.

Taken together, our experiments reveal the presence of a novel transcript we term *NICI*, which is transcriptionally activated by the HIF-1 transcription factor. An intact *NICI* transcript is both necessary and sufficient for the hypoxic transcriptional activation of *SLC2A3* by HIF and is involved in regulating glucose consumption and cell proliferation.

## Discussion

HIFs coordinate a complex transcriptional program that drives cell adaptation to hypoxia. Regulation of established protein-coding genes has been investigated in detail in single gene analyses or genome-wide approaches. These studies revealed that HIFs mainly act in cis by occupying promoter-proximal or promoter-distal regulatory elements to induce gene expression (3, 32, 33). In this respect, we have previously shown that HIF frequently binds to enhancers and that gene regulation may occur through looping of these distant sites to target promoters (28, 29, 34). Here we describe an alternative mechanism by which HIFs may regulate distant genes in trans through induction of a long noncoding RNA. Our experiments using ChIP- and RNA-Seq, chromatin capture assays, coupled with genome editing and artificial transcriptional activators in a variety of primary and transformed cell models identify the promoter-associated long noncoding RNA *NICI* and describe its functional role for hypoxic *SLC2A3* regulation.

Local control of gene transcription has been described as one of the main functions of long noncoding RNAs (31). Recent reports have highlighted this way of fine-tuning transcriptional activity with important relevance for human diseases. For example, in a recent genome-wide screen testing resistance to

## Long noncoding RNA *NICI* regulates *GLUT3* expression

BRAF inhibitors in melanoma cells, CRISPR/Cas9-mediated activation of more than 10,000 lncRNAs revealed 16 candidate loci conferring resistance to BRAF inhibition (25). Importantly, analysis of a subset of these lncRNA showed that activation of lncRNAs can lead to differential transcriptional activity of protein-coding genes in genomic vicinity (within 1 Mb) of the respective lncRNA locus. These findings are in accordance with our results obtained in experiments with CRISPR/Cas9-VPR-activated *NICI* expression, which led to increased *SLC2A3* RNA levels.

The HIF-binding site in the *NICI* promoter was identified in an earlier report using HIF ChIP-Seq in human umbilical vein endothelial cells (35). The authors also detected regulation of *SLC2A3* and attributed enhancer-like functions to the HIF-binding site using 3C and reporter assays. Using Capture-C assays, we did not detect chromatin looping of the *SLC2A3* promoter to the HIF-binding site within the *NICI* locus in three different cell lines. The discrepancy between the two studies might be caused by the different methods applied or by the different cell lines used having potentially diverse chromatin configurations in this region. We detected chromatin interactions of the *SLC2A3* promoter with a genomic region ~24 kb upstream of the *SLC2A3* gene and 10 kb downstream of *NICI*. This site has been described to interact with the *NICI* locus and may therefore mediate the effect of *NICI* on *SLC2A3* (35).

Both HIF-binding and expression of long noncoding RNAs can vary considerably between cell types. Therefore, the conserved regulation of both *SLC2A3* and *NICI* by HIF across many cell types is noteworthy. Indeed, this may have contributed to the detection of the transcript and the regulatory loop linking *NICI* to *SLC2A3* expression in the current work. Of note, and in contrast to *SLC2A1* and most glycolytic genes which are regulated by HIF-1 in many species including humans and mice, *SLC2A3* is not regulated by loss of VHL in the renal epithelium of mice (Fig. S9). Consistent with this and in line with the poor conservation of the noncoding transcriptome the *NICI* locus is not conserved in mice (data not shown) (36). This suggests either that *NICI* expression is species specific or that it is expressed from a different locus and/or in a different form in other species. Therefore, *NICI* may contribute to fine-tuning of hypoxic *SLC2A3* expression specifically in humans.

We also considered the possibility of an alternative promoter usage for *SLC2A3* expression at this site. However, we could not detect spliced RNA products that cover both the *NICI* coding region and fragments of the *SLC2A3* transcript in PCR analyses (data not shown). Furthermore, we could not detect RNApol2 binding or transcripts in the putative intronic region covering the 35 kb from the *NICI* promoter to the *SLC2A3* gene in any of our sequencing experiments. Confirming our observations, recent studies describe this locus as a region resembling features of a promoter-associated long noncoding RNA (23, 24). We conclude that *NICI* is a genuine long noncoding RNA with low protein coding potential.

Glucose transporters have a remarkable tissue-specific expression pattern (37). For example, *SLC2A3/GLUT3* is mainly detectable in the brain and the testis (38). Earlier studies together with our mRNA expression analyses and a meta-analysis of hypoxia-inducible genes suggest that expression of

*SLC2A3/GLUT3* is induced in tumor cells and under control of many tumor-associated pathways including the HIF-pathway (15, 39). These observations would be in agreement with an important role of this high-affinity glucose transporter in securing energy supply and cell survival in hypoxic areas of certain tumors that have outgrown sufficiently oxygenated regions. Because fast growth is a feature of many aggressive tumors, increased expression of glucose transporters is associated with poor survival in many cancers (39). Therefore, pharmacological targeting of expression or function of glucose transporters is a promising strategy in oncology research (40). A recent study has highlighted this approach in glioblastoma patients in which high *GLUT3* expression associates with an unfavorable outcome (41). Targeting cells which were dependent on *GLUT3* by interfering with integrin and PAK4-YAP/TAZ signaling reduced *GLUT3* expression and tumor cell viability, introducing a novel approach to treat this aggressive tumor type (41).

Further experiments will be necessary to uncover the detailed mode of action of *NICI* on *SLC2A3* expression. The mechanism might involve direct recruitment of members of the transcriptional machinery or other transcription factors to the *SLC2A3* promoter or the enhancer site interacting with the promoter. It is possible that *NICI* is involved in modulating the epigenetic signature at the *SLC2A3* gene to permit increased transcription. It will also be of interest to examine the function of *NICI* in diseases associated with hypoxia signaling such as ccRCC. Furthermore, a detailed analysis of the noncoding transcriptome regulated by hypoxia in different cells and settings might reveal more such loci with co-regulation of lncRNAs and protein-coding genes maybe in a more cell type-specific fashion.

## Experimental procedures

### Cell culture

Human PTCs were obtained from the healthy kidney cortical tissue of patients undergoing tumor nephrectomy. Isolation of these cells was approved by the local ethical committee at the University Erlangen-Nürnberg. Investigations were performed in accordance with the principles of the Declaration of Helsinki. HKC-8 cells were from L. Racusen. 786-O pVHL re-expressing cells were a gift of W. G. Kaelin, Jr. RCC4 cells were provided by C. H. Buys. RCC10 cells were from M. Wiesener. HK-2 and HUH-7 were kindly provided by C. Warnecke. Human umbilical vein endothelial cells were a gift from the Department of Molecular Cardiology, University Erlangen-Nürnberg. HeLa, MCF-7, Hep3B, HepG2, HEK293T, T47D, and HT1080 cells were purchased from American Type Culture Collection. PTCs were cultured in DMEM and Ham's F-12 supplemented with 2 mM L-glutamine, 100 units ml<sup>-1</sup> penicillin, 100 μg ml<sup>-1</sup> streptomycin, 5g ml<sup>-1</sup> insulin, 5 μg ml<sup>-1</sup> transferrin, 5 ng ml<sup>-1</sup> selenium (Sigma), 10 ng ml<sup>-1</sup> triiodothyronine, 1 mg hydrocortisone, and 100 μg ml<sup>-1</sup> epidermal growth factor (PeproTech) (42). HKC-8 cells were grown as described previously (43). HT1080 cells were cultured in minimal essential medium supplemented with 10% fetal calf serum, 2 mM L-glutamine, 100 units ml<sup>-1</sup> penicillin

and 100  $\mu\text{g ml}^{-1}$  streptomycin. All other cell lines were grown in DMEM supplemented with 10% fetal calf serum, 2 mM L-glutamine, 100 units  $\text{ml}^{-1}$  penicillin and 100  $\mu\text{g ml}^{-1}$  streptomycin. Subconfluent cell cultures were exposed to 1 mM DMOG (Cayman Chemical Co.) 16 h before harvest.

#### RNA isolation and quantification by qPCR

Total RNA from cell culture was isolated using the peqGOLD Total RNA Kit or TriFast Reagent (VWR peqlab) according to manufacturer's instructions. Transcription of RNA to cDNA was performed using the High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific). qPCRs were performed using Maxima SYBR Green/ROX qPCR Master Mix (Thermo Fisher Scientific) on a StepOnePlus Real-Time PCR cyclers (Applied Biosystems). Primers are listed in Table S2.

#### siRNA and ASO transfection

siRNA against *Drosophila* HIF (control siRNA), HIF-1 $\alpha$ , and HIF-2 $\alpha$  has been described previously (44) (Table S2). siRNAs were transfected using SAINT red reagent (Synvolux) with a final concentration of 40 nM. Scrambled and NEAT1 ASO controls (45) and NIC1 ASOs (Integrated DNA Technologies) were transfected using Lipofectamine 3000 reagent (Invitrogen) with a final concentration of 100 nM. ASO sequences are given in Table S2.

#### ChIP

ChIP assays were performed using the Upstate Protocol (Millipore) with minor modifications as described (46, 47). Cells were crosslinked by adding 1% (w/v) formaldehyde. Crosslinking was quenched by addition of 125 mM glycine. Cells were scraped off and lysed in 1 ml SDS lysis buffer. Genomic DNA in cell lysates was fragmented using a Bioruptor Plus sonicator (Diagenode). For immunoprecipitations, 6  $\mu\text{l}$  of antibody solutions against HIF-1 $\alpha$  (rabbit polyclonal, Cayman Chemicals, Cay10006421) and HIF-1 $\beta$  (rabbit polyclonal, Novus Biologicals, NB100-110) or 10  $\mu\text{l}$  of RNAPol2 antibody (Santa Cruz Biotechnology, sc-899) were used. Rabbit serum served as negative control. Chromatin-antibody complexes were pulled down by Protein A agarose beads (Millipore). After reversal of crosslinking by heat, DNA was isolated by phenol-chloroform extraction. Samples were analyzed by ChIP-qPCR using Maxima SYBR green/ROX qPCR Master Mix on a StepOnePlus Real-Time cyclers (Applied Biosystems). Primers are listed in Table S2.

#### Capture-C assay

Experiments were performed as described previously (29, 30). Briefly, 3C libraries were generated from 786-O, RCC4, and MCF-7 cells with DpnII and were sonicated to 200 bp. Indexed libraries were generated with NEBNext reagents (E6000, E7335, New England Biolabs). Capture enrichment was performed with the SeqCap EZ system (06953212001, Roche/Nimblegen) following the manufacturer's instructions. 1–2  $\mu\text{g}$  of indexed library was incubated with 13 pmol of a pool of biotinylated oligos (Integrated DNA Technologies or Sigma). A double capture protocol was followed with 48-h and 24-h hybridizations

(30). Capture efficiency was determined with qPCR relative to a standard curve of genomic DNA prior to sequencing.

#### Genome editing

For genome editing, the GeneArt CRISPR Nuclease Vector with GFP Reporter Kit (Invitrogen) was used. The gRNA was designed according to algorithms provided by the Zhang lab. Cloning of CRISPR/Cas9 plasmids followed the manufacturer's instructions. A total of  $6 \times 10^4$  cells were transfected with 3  $\mu\text{g}$  plasmid using Lipofectamine 3000 (Invitrogen). Single-cell clones were generated by dilution. For mutation screens, genomic DNA of each clone was isolated by phenol-chloroform extraction and the CRISPR/Cas9 target region was amplified by PCR. PCR products were resolved in a 15% nondenaturing polyacrylamide gel. Primers are listed in Table S2. Genomic DNA of clones with putative indel mutations was amplified by PCR, cloned into a pGL3-Basic vector (Promega), and analyzed by Sanger sequencing.

#### CRISPR/Cas9 mediated gene activation

For CRISPR/Cas9-mediated activation of gene expression we used the SP-dCas9-VPR artificial activator (VP64-p65-Rta; Addgene 63798) in combination with a pSPgRNA plasmid (Addgene 47108) as a carrier for the specific gRNA (48). The gRNAs were designed according to algorithms provided by the Zhang lab. For cloning of the gRNA into the carrier vector we used the restriction enzyme BbsI according to the manufacturer's instructions. A total of  $3 \times 10^4$  cells were transfected with 375 ng CRISPR/Cas9-VPR in combination with 125 ng pSPgRNA-Nici guide using Lipofectamine 3000 (Invitrogen). Total RNA was isolated as described 48 h after transfection.

#### Immunoblotting

Cells were lysed in Urea/SDS or RIPA buffer added with  $1 \times$  cComplete Protease inhibitor (Roche) and 5 mM DTT. Proteins were fractionated by size in 10% (w/v) denaturing SDS-polyacrylamide gels and transferred onto polyvinylidene difluoride membranes. For detection, antibodies anti-HIF-1 $\alpha$  (1:1000, rabbit polyclonal, Cayman Chemicals, Cay10006421), anti-HIF-2 $\alpha$  (1:1000, goat polyclonal, R&D Systems, AF2997), anti-Glut3 (1:400, rabbit polyclonal, Abcam, ab15311), and anti- $\beta$ -actin-HRP (1:60,000, mouse monoclonal (AC-15), Sigma-Aldrich, A3854) and horseradish peroxidase-conjugated anti-rabbit (1:1000) and anti-goat (1:1000) secondary antibodies (Dako) were used. Protein signal was detected using Pierce ECL Plus Western blotting substrate (Thermo Fisher Scientific). Immunoreactive bands were quantified using the ImageQuant TL 8.1 software (GE Healthcare) and normalized to signals for  $\beta$ -actin. Specificity of the antibodies was validated using siRNA-mediated knock-down of the respective proteins (for HIF-1 $\alpha$ , HIF-2 $\alpha$  please compare Fig. S3) (SLC2A3 data not shown).

#### Healthy kidney and tumor samples

Healthy human kidney cortical tissue and tumor tissue from patients undergoing tumor nephrectomy was kindly provided by the Comprehensive Cancer Centre (CCC) at the Universitätsklinikum Erlangen. The use of this tissue was approved by

## Long noncoding RNA NIC1 regulates GLUT3 expression

the local ethical committee at the University of Erlangen-Nürnberg and each patient gave informed consent. Investigations were performed in accordance with the principles of the Declaration of Helsinki. Tumor and normal kidney samples were examined by an expert pathologist. Pairs of normal kidney and tumor tissue from 126 ccRCC and 35 non-ccRCC patients were used. Fresh frozen tissue was used to isolate total RNA using the peqGOLD Total RNA Kit and expression of genes was measured as described above.

### High-throughput sequencing data

High-throughput sequencing experiments have been performed as described previously (4, 26, 27, 29). Data are available at the GEO and EMBL-EBI Array Express data bases with accession codes GSE78113, GSE120887, GSE28352, GSE101064, GSE54172, E-MTAB-1994, and E-MTAB-1995.

### Proliferation assay

Cells were plated in triplicates at  $4 \times 10^3$  in 96-well tissue culture plates in 100  $\mu$ l medium. The next day cells were exposed to 1% O<sub>2</sub> for 48 or 96 h in a hypoxic incubator. An MTS assay was conducted after 0, 48, or 96 h of hypoxic exposure according to the manufacturer's instructions (Promega). Absorbance was measured in a microplate reader and normalized to background values derived from medium alone.

### Glucose consumption and lactate production

Cells were plated at a density of  $8 \times 10^4$  in a 6-well plate. The next day cells were incubated with 1 mM DMOG in fresh growth media. After 24 h the supernatant was analyzed for glucose and lactate content using a ABL800 FLEX blood gas analyzer (Radiometer). Values from medium alone (from the beginning of the experiment) were used to calculate percentage of glucose content in the samples.

### Statistical analysis

Statistical analyses were performed using a one-sample, a two-sample, or a paired *t* test as applicable (GraphPad Prism version 8.00 and Microsoft Excel 2016).

**Author contributions**—V. Lauer, S. G., J. P., V. Lafleur, O. L., H. C., F. K., A. H., and J. S. data curation; V. Lauer, S. G., J. P., V. Lafleur, B. W., A. Y., M. L. C., and J. S. formal analysis; V. Lauer, S. G., J. P., V. Lafleur, O. L., H. C., A. H., B. W., M. L. C., D. R. M., and J. S. investigation; V. Lauer, P. J. R., D. R. M., and J. S. writing—original draft; F. K. software; F. K. visualization; A. Y., P. J. R., and J. S. methodology; P. J. R., D. R. M., and J. S. funding acquisition; J. S. conceptualization; J. S. supervision.

**Acknowledgments**—We thank Stephanie Palffy, Astrid Ebenau-Eggers, and Margot Rehm for excellent technical assistance. We thank the Comprehensive Cancer Center Erlangen (CCC Erlangen-EMN) at Universitätsklinikum Erlangen for providing tissue specimens. We thank the Oxford Genomics Centre at the Wellcome Centre for Human Genetics (funded by Wellcome Trust Grant 203141/Z/16/Z) and the Core Unit for Next Generation Sequencing at the Universitätsklinikum Erlangen for the generation and initial processing of the sequencing data.

## References

1. Semenza, G. L. (2012) Hypoxia-inducible factors in physiology and medicine. *Cell* **148**, 399–408 [CrossRef Medline](#)
2. Kaelin, W. G., Jr., and Ratcliffe, P. J. (2008) Oxygen sensing by metazoans: The central role of the HIF hydroxylase pathway. *Mol. Cell* **30**, 393–402 [CrossRef Medline](#)
3. Xia, X., Lemieux, M. E., Li, W., Carroll, J. S., Brown, M., Liu, X. S., and Kung, A. L. (2009) Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis. *Proc. Natl. Acad. Sci. U.S.A.* **106**, 4260–4265 [CrossRef Medline](#)
4. Schödel, J., Oikonomopoulos, S., Ragoussis, J., Pugh, C. W., Ratcliffe, P. J., and Mole, D. R. (2011) High-resolution genome-wide mapping of HIF-binding sites by ChIP-Seq. *Blood* **117**, e207–e217 [CrossRef Medline](#)
5. Maxwell, P. H., and Eckardt, K. U. (2016) HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond. *Nat. Rev. Nephrol.* **12**, 157–168 [CrossRef Medline](#)
6. Keith, B., Johnson, R. S., and Simon, M. C. (2011) HIF1 $\alpha$  and HIF2 $\alpha$ : Sibling rivalry in hypoxic tumour growth and progression. *Nat. Rev. Cancer* **12**, 9–22 [CrossRef Medline](#)
7. Gnarr, J. R., Tory, K., Weng, Y., Schmidt, L., Wei, M. H., Li, H., Latif, F., Liu, S., Chen, F., and Duh, F. M. (1994) Mutations of the VHL tumour suppressor gene in renal carcinoma. *Nat. Genet.* **7**, 85–90 [CrossRef Medline](#)
8. Raval, R. R., Lau, K. W., Tran, M. G., Sowter, H. M., Mandriota, S. J., Li, J. L., Pugh, C. W., Maxwell, P. H., Harris, A. L., and Ratcliffe, P. J. (2005) Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. *Mol. Cell Biol.* **25**, 5675–5686 [CrossRef Medline](#)
9. Shen, C., Beroukhi, R., Schumacher, S. E., Zhou, J., Chang, M., Signoretto, S., and Kaelin, W. G., Jr. (2011) Genetic and functional studies implicate HIF1 $\alpha$  as a 14q kidney cancer suppressor gene. *Cancer Discov.* **1**, 222–235 [CrossRef Medline](#)
10. Kondo, K., Kim, W. Y., Lechpammer, M., and Kaelin, W. G., Jr. (2003) Inhibition of HIF2 $\alpha$  is sufficient to suppress pVHL-defective tumor growth. *PLoS Biol.* **1**, E83 [CrossRef Medline](#)
11. Maxwell, P. H., Wiesener, M. S., Chang, G. W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., and Ratcliffe, P. J. (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. *Nature* **399**, 271–275 [CrossRef Medline](#)
12. Xie, H., and Simon, M. C. (2017) Oxygen availability and metabolic reprogramming in cancer. *J. Biol. Chem.* **292**, 16825–16832 [CrossRef Medline](#)
13. Maxwell, P. H., Dachs, G. U., Gleadle, J. M., Nicholls, L. G., Harris, A. L., Stratford, I. J., Hankinson, O., Pugh, C. W., and Ratcliffe, P. J. (1997) Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. *Proc. Natl. Acad. Sci. U.S.A.* **94**, 8104–8109 [CrossRef Medline](#)
14. Chen, C., Pore, N., Behrooz, A., Ismail-Beigi, F., and Maity, A. (2001) Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. *J. Biol. Chem.* **276**, 9519–9525 [CrossRef Medline](#)
15. Ortiz-Barahona, A., Villar, D., Pescador, N., Amigo, J., and del Peso, L. (2010) Genome-wide identification of hypoxia-inducible factor binding sites and target genes by a probabilistic model integrating transcription-profiling data and *in silico* binding site prediction. *Nucleic Acids Res.* **38**, 2332–2345 [CrossRef Medline](#)
16. Fang, H. Y., Hughes, R., Murdoch, C., Coffelt, S. B., Biswas, S. K., Harris, A. L., Johnson, R. S., Imityaz, H. Z., Simon, M. C., Fredlund, E., Greten, F. R., Rius, J., and Lewis, C. E. (2009) Hypoxia-inducible factors 1 and 2 are important transcriptional effectors in primary macrophages experiencing hypoxia. *Blood* **114**, 844–859 [CrossRef Medline](#)
17. Vannucci, S. J., Reinhart, R., Maher, F., Bondy, C. A., Lee, W. H., Vannucci, R. C., and Simpson, I. A. (1998) Alterations in GLUT1 and GLUT3 glucose transporter gene expression following unilateral hypoxia-ischemia in the immature rat brain. *Brain Res. Dev. Brain Res* **107**, 255–264 [CrossRef Medline](#)

18. Choudhry, H., Schödel, J., Oikonomopoulos, S., Camps, C., Grampp, S., Harris, A. L., Ratcliffe, P. J., Ragoussis, J., and Mole, D. R. (2014) Extensive regulation of the non-coding transcriptome by hypoxia: Role of HIF in releasing paused RNAPol2. *EMBO Rep.* **15**, 70–76 [CrossRef Medline](#)
19. Valera, V. A., Walter, B. A., Linehan, W. M., and Merino, M. J. (2011) Regulatory effects of microRNA-92 (miR-92) on VHL gene expression and the hypoxic activation of miR-210 in clear cell renal cell carcinoma. *J. Cancer* **2**, 515–526 [CrossRef Medline](#)
20. Camps, C., Buffa, F. M., Colella, S., Moore, J., Sotiriou, C., Sheldon, H., Harris, A. L., Gleadle, J. M., and Ragoussis, J. (2008) hsa-miR-210 is induced by hypoxia and is an independent prognostic factor in breast cancer. *Clin. Cancer Res.* **14**, 1340–1348 [CrossRef Medline](#)
21. Choudhry, H., Albukhari, A., Morotti, M., Haider, S., Moralli, D., Smythies, J., Schödel, J., Green, C. M., Camps, C., Buffa, F., Ratcliffe, P., Ragoussis, J., Harris, A. L., and Mole, D. R. (2015) Tumor hypoxia induces nuclear paraspeckle formation through HIF-2 $\alpha$  dependent transcriptional activation of NEAT1 leading to cancer cell survival. *Oncogene* **34**, 4546 [CrossRef Medline](#)
22. Iyer, M. K., Niknafs, Y. S., Malik, R., Singhal, U., Sahu, A., Hosono, Y., Barrette, T. R., Prensner, J. R., Evans, J. R., Zhao, S., Poliakov, A., Cao, X., Dhanasekaran, S. M., Wu, Y. M., Robinson, D. R., Beer, D. G., Feng, F. Y., Iyer, H. K., and Chinnaiyan, A. M. (2015) The landscape of long noncoding RNAs in the human transcriptome. *Nat. Genet.* **47**, 199–208 [CrossRef Medline](#)
23. FANTOM Consortium and the RIKEN PMI and CLST (DGT), Forrest, A. R., Kawaji, H., Rehli, M., Baillie, J. K., de Hoon, M. J., Haberle, V., Lassmann, T., Kulakovskiy, I. V., Lizio, M., Itoh, M., Andersson, R., Mungall, C. J., Meehan, T. F., Schmeier, S., *et al.* (2014) A promoter-level mammalian expression atlas. *Nature* **507**, 462–470 [CrossRef Medline](#)
24. Andersson, R., Gebhard, C., Miguel-Escalada, I., Hoof, I., Bornholdt, J., Boyd, M., Chen, Y., Zhao, X., Schmidl, C., Suzuki, T., Ntini, E., Arner, E., Valen, E., Li, K., Schwarzfischer, L., *et al.* (2014) An atlas of active enhancers across human cell types and tissues. *Nature* **507**, 455–461 [CrossRef Medline](#)
25. Joung, J., Engreitt, J. M., Konermann, S., Abudayyeh, O. O., Verdine, V. K., Aguet, F., Gootenberg, J. S., Sanjana, N. E., Wright, J. B., Fulco, C. P., Tseng, Y. Y., Yoon, C. H., Boehm, J. S., Lander, E. S., and Zhang, F. (2017) Genome-scale activation screen identifies a lncRNA locus regulating a gene neighbourhood. *Nature* **548**, 343–346 [CrossRef Medline](#)
26. Salama, R., Masson, N., Simpson, P., Sciesielski, L. K., Sun, M., Tian, Y. M., Ratcliffe, P. J., and Mole, D. R. (2015) Heterogeneous effects of direct hypoxia pathway activation in kidney cancer. *PLoS One* **10**, e0134645 [CrossRef Medline](#)
27. Smythies, J. A., Sun, M., Masson, N., Salama, R., Simpson, P. D., Murray, E., Neumann, V., Cockman, M. E., Choudhry, H., Ratcliffe, P. J., and Mole, D. R. (2019) Inherent DNA-binding specificities of the HIF-1 $\alpha$  and HIF-2 $\alpha$  transcription factors in chromatin. *EMBO Rep.* **20**, e46401 [CrossRef Medline](#)
28. Grampp, S., Platt, J. L., Lauer, V., Salama, R., Kranz, F., Neumann, V. K., Wach, S., Stöhr, C., Hartmann, A., Eckardt, K. U., Ratcliffe, P. J., Mole, D. R., and Schödel, J. (2016) Genetic variation at the 8q24.21 renal cancer susceptibility locus affects HIF binding to a MYC enhancer. *Nat. Commun.* **7**, 13183 [CrossRef Medline](#)
29. Platt, J. L., Salama, R., Smythies, J., Choudhry, H., Davies, J. O., Hughes, J. R., Ratcliffe, P. J., and Mole, D. R. (2016) Capture-C reveals preformed chromatin interactions between HIF-binding sites and distant promoters. *EMBO Rep.* **17**, 1410–1421 [CrossRef Medline](#)
30. Davies, J. O., Telenius, J. M., McGowan, S. J., Roberts, N. A., Taylor, S., Higgs, D. R., and Hughes, J. R. (2016) Multiplexed analysis of chromosome conformation at vastly improved sensitivity. *Nat. Methods* **13**, 74–80 [CrossRef Medline](#)
31. Vance, K. W., and Ponting, C. P. (2014) Transcriptional regulatory functions of nuclear long noncoding RNAs. *Trends Genet.* **30**, 348–355 [CrossRef Medline](#)
32. Xia, X., and Kung, A. L. (2009) Preferential binding of HIF-1 to transcriptionally active loci determines cell-type specific response to hypoxia. *Genome Biol.* **10**, R113 [CrossRef Medline](#)
33. Schödel, J., Mole, D. R., and Ratcliffe, P. J. (2013) Pan-genomic binding of hypoxia-inducible transcription factors. *Biol. Chem.* **394**, 507–517 [CrossRef Medline](#)
34. Schödel, J., Bardella, C., Sciesielski, L. K., Brown, J. M., Pugh, C. W., Buckle, V., Tomlinson, I. P., Ratcliffe, P. J., and Mole, D. R. (2012) Common genetic variants at the 11q13.3 renal cancer susceptibility locus influence binding of HIF to an enhancer of cyclin D1 expression. *Nat. Genet.* **44**, 420–425, S1–S2 [CrossRef Medline](#)
35. Mimura, I., Nangaku, M., Kanki, Y., Tsutsumi, S., Inoue, T., Kohro, T., Yamamoto, S., Fujita, T., Shimamura, T., Suehiro, J., Taguchi, A., Kobayashi, M., Tanimura, K., Inagaki, T., Tanaka, T., *et al.* (2012) Dynamic change of chromatin conformation in response to hypoxia enhances the expression of GLUT3 (SLC2A3) by cooperative interaction of hypoxia-inducible factor 1 and KDM3A. *Mol. Cell Biol.* **32**, 3018–3032 [CrossRef Medline](#)
36. Ulitsky, I. (2016) Evolution to the rescue: Using comparative genomics to understand long non-coding RNAs. *Nat. Rev. Genet.* **17**, 601–614 [CrossRef Medline](#)
37. Scheepers, A., Joost, H. G., and Schürmann, A. (2004) The glucose transporter families SGLT and GLUT: Molecular basis of normal and aberrant function. *J. Parenter. Enteral Nutr.* **28**, 364–371 [CrossRef Medline](#)
38. Simpson, I. A., Dwyer, D., Malide, D., Moley, K. H., Travis, A., and Vannucci, S. J. (2008) The facilitative glucose transporter GLUT3: 20 years of distinction. *Am. J. Physiol. Endocrinol. Metab.* **295**, E242–E253 [CrossRef Medline](#)
39. Macheda, M. L., Rogers, S., and Best, J. D. (2005) Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. *J. Cell Physiol.* **202**, 654–662 [CrossRef Medline](#)
40. Ancey, P. B., Contat, C., and Meylan, E. (2018) Glucose transporters in cancer—from tumor cells to the tumor microenvironment. *FEBS J.* **285**, 2926–2943 [CrossRef Medline](#)
41. Cosset, É., Ilmjärv, S., Dutoit, V., Elliott, K., von Schalscha, T., Carmargo, M. F., Reiss, A., Moroishi, T., Seguin, L., Gomez, G., Moo, J. S., Preynat-Seauve, O., Krause, K. H., Chneiweiss, H., Sarkaria, J. N., *et al.* (2017) Glut3 addiction is a druggable vulnerability for a molecularly defined subpopulation of glioblastoma. *Cancer Cell* **32**, 856–868 [CrossRef Medline](#)
42. Keller, C., Kroening, S., Zuehlke, J., Kunath, F., Krueger, B., and Goppelt-Strube, M. (2012) Distinct mesenchymal alterations in N-cadherin and E-cadherin positive primary renal epithelial cells. *PLoS One* **7**, e43584 [CrossRef Medline](#)
43. Racusen, L. C., Monteil, C., Sgrignoli, A., Lucskay, M., Marouillat, S., Rhim, J. G., and Morin, J. P. (1997) Cell lines with extended *in vitro* growth potential from human renal proximal tubule: Characterization, response to inducers, and comparison with established cell lines. *J. Lab. Clin. Med.* **129**, 318–329 [CrossRef Medline](#)
44. Elvidge, G. P., Glenny, L., Appelhoff, R. J., Ratcliffe, P. J., Ragoussis, J., and Gleadle, J. M. (2006) Concordant regulation of gene expression by hypoxia and 2-oxoglutarate-dependent dioxygenase inhibition: The role of HIF-1 $\alpha$ , HIF-2 $\alpha$ , and other pathways. *J. Biol. Chem.* **281**, 15215–15226 [CrossRef Medline](#)
45. Choudhry, H., Albukhari, A., Morotti, M., Haider, S., Moralli, D., Smythies, J., Schödel, J., Green, C. M., Camps, C., Buffa, F., Ratcliffe, P., Ragoussis, J., Harris, A. L., and Mole, D. R. (2015) Tumor hypoxia induces nuclear paraspeckle formation through HIF-2 $\alpha$  dependent transcriptional activation of NEAT1 leading to cancer cell survival. *Oncogene* **34**, 4482–4490 [CrossRef Medline](#)
46. Lau, K. W., Tian, Y. M., Raval, R. R., Ratcliffe, P. J., and Pugh, C. W. (2007) Target gene selectivity of hypoxia-inducible factor- $\alpha$  in renal cancer cells is conveyed by post-DNA-binding mechanisms. *Br. J. Cancer* **96**, 1284–1292 [CrossRef Medline](#)
47. Mole, D. R., Blancher, C., Copley, R. R., Pollard, P. J., Gleadle, J. M., Ragoussis, J., and Ratcliffe, P. J. (2009) Genome-wide association of hypoxia-inducible factor (HIF)-1 $\alpha$  and HIF-2 $\alpha$  DNA binding with expression profiling of hypoxia-inducible transcripts. *J. Biol. Chem.* **284**, 16767–16775 [CrossRef Medline](#)
48. Chavez, A., Scheiman, J., Vora, S., Pruitt, B. W., Tuttle, M., Iyer, E. P. R., Lin, S., Kiani, S., Guzman, C. D., Wiegand, D. J., Ter-Ovanesyan, D., Braff,

## Long noncoding RNA NIC1 regulates GLUT3 expression

- J. L., Davidsohn, N., Housden, B. E., Perrimon, N., Weiss, R., Aach, J., Collins, J. J., and Church, G. M. (2015) Highly efficient Cas9-mediated transcriptional programming. *Nat. Methods* **12**, 326–328 [CrossRef](#) [Medline](#)
49. Anaya, J. (2016) OncoLnc: Linking TCGA survival data to mRNAs, miRNAs, and lncRNAs. *PeerJ Comp. Sci.* **2**, e67 [CrossRef](#)
50. Iyer, M.K., Niknafs, Y.S., Malik, R., Singhal, U., Sahu, A., Hosono, Y., Barrette, T.R., Prensner, J.R., Evans, J.R., Zhao, S., Poliakov, A., Cao, X., Dhannasekaran, S.M., Wu, Y.M., Robinson, D.R., Beer, D.G., Feng, F.Y., Iyer, H.K., and Chinnaiyan, A.M. (2015) The landscape of long noncoding RNAs in the human transcriptome. *Nat. Genet.* **47**, 199–208 [CrossRef](#) [Medline](#)